Chiropractic Algona IA Weight Loss

Tirzepatide for Weight Loss

Taffe Wellness Center
105 S Phillips St
Algona, IA 50511
(515) 575-9123

Taffe Wellness Center
514 1st Ave
Armstrong, IA 50514
 (712) 868-3265




Telehealth Consultations Available

Tirzepatide for Weight Loss

Taffe Wellness Center
105 S Phillips St
Algona, IA 50511
(515) 575-9123

Taffe Wellness Center
514 1st Ave
Armstrong, IA 50514
 (712) 868-3265


AN Appointment


Telehealth Consultations Available

We're seeing fantastic results helping people with the following:

  • Rapid weight loss

  • Improved insulin sensitivity

  • Reduced Blood Sugar

  • Minimal Side Effects

  • Rapid weight loss

  • Improved insulin sensitivity

  • Reduced Blood Sugar

  • Minimal Side Effects

A New Option for Weight Loss

Chiropractic Algona IA Megan Bradley

Megan Bradley, ARNP


    Tirzepatide is a peptide made up of 39 amino acids. It has been shown to significantly reduce food intake, decrease cravings and induce rapid weight loss in clinical trials. Tirzepatide has been touted as "Ozempic version 2.0" - the new generation glucagon-like peptide 1 (GLP-1).

    Tirzepatide can be defined as the direct successor to the Semaglutide peptide, better known by its trade name, Ozempic. 2 years after its introduction to the weight loss drug market, Ozempic is already one of the best-selling drugs in America, and for good reason: it works. The draw back of semaglutide is its reported side effects. Tirzepatide is proving to have relatively limited side effects with an added bonus of lipolysis aka "fat burning" independent of caloric intake.


    • It induces a very significant weight loss in a short time.
    • Improves insulin sensitivity.
    • Reduces blood sugar.
    • It has much less side effects than the other medicines that induce weight loss.

Request An Appointment

It's Time To Get the Results You Deserve!

Semaglutide (brand name Ozempic) and Tirzepatide belong to the class of glucagon-like peptides 1 (GLP-1).

GLP-1 is an important 'incretin' hormone. Incretin hormones are a group of hormones that are released in the gastrointestinal tract after eating and stimulate insulin production. These hormones help regulate the absorption of glucose into the bloodstream and prevent the rise in blood sugar after a meal.

GLP-1 not only increases insulin secretion, but increases β cell proliferation and survival, suppresses glucagon secretion, delays gastric emptying, and suppresses appetite. All these actions contribute to its antidiabetic and anti-obesity effects.

Ultimately this process led to the creation and commercialization of Semaglutide (Ozempic).

And that's how, in June 2021, it became the first FDA-approved weight-control drug since 2014.

Shortly after, in May 2022, the FDA approved the marketing of a new generation GLP-1 agonist peptide: Tirzepatide (trade name Mounjaro).

Semaglutide, is marketed under the names Ozempic and Rybelsus for diabetes and Wegovy for weight loss. Mounjaro is a dual incretin or a “twincreatin” that stimulates two satiety hormone receptors: GIP and GLP-1. The average weight loss with tirzepatide is an astonishing 22.5%.

GIP = glucose-dependent insulinotropic polypeptide

GLP-1 = glucagon-like peptide-1

A true comparison between semaglutide and tirzepatide has not been done because in recently released research, a lower 1 mg dose of semaglutide was compared to the highest dose of tirzepatide. Many say this was an unfair comparison and if the full 2.4 mg dose of semaglutide was used the difference may have been smaller or nonexistent. Weight loss numbers in Mounjaro studies are higher than other weight loss medications and are similar to the results seen with bariatric surgery.

In other words, unlike semaglutide which only acts on GLP-1, tirzepatide acts not only on GLP-1 but also on GIP.

GIP stimulation grants the following benefits:

Protection against Hypoglycemia: It improves the elimination of triglycerides and the sensitivity of adipose tissue to insulin, which can prevent the deposition of ectopic fat.

It does not have as many tolerability problems (nausea, diarrhea...) as semaglutide, which usually causes these side effects quite pronouncedly. Nausea due to decreased gastric emptying, person eats too much, food sits in stomach longer causing the adverse symptoms.

Clinical trials between Tirzepatide and Semaglutide show that Tirzepatide is a far superior option in several respects:

  • More patients reach their 5%, 10% and 15% weight loss goals
  • Greater absolute and relative reduction in total body weight
  • Increased reduction in glycosylated hemoglobin (HbA1c)
  • Less tolerability side effects

The best weight loss results are seen when weight loss medications are combined with intensive lifestyle modification and calorie restriction. The major benefit of weight loss is improvement comorbidities of obesity such as diabetes, high blood pressure, abnormal blood lipids and heart disease which can be seen with as little as 5% weight loss.

Remember, tirzepatide or any other weight loss medication is not a magic bullet but simply a tool to lower appetite for sustained calorie reduction. There is no perfect medication for obesity. A medication that may work for a family member or a friend may not be the ideal medication for you. Treating obesity can be complicated so it is best to work with a knowledgeable health care professional who is dedicated to working with you over the long term.

Researchers have conducted numerous studies on BPC-157 that have been showing protective effects that extend from benefits from the stomach and intestinal tracts only.

BPC 157 Peptides are made of 15 Amino Acids and are derived from human gastric juices. A lot of experiments have shown how BPC 157 Peptides can heal different kinds of tissues. These include:

  • Tendons
  • Muscles
  • Nervous System
  • And Ligaments

Thus, it’s pretty much safe to say that patients who suffer discomfort from those mentioned above can benefit from BPC 157 healing work as this peptide can increase the blood flow going back to the areas of injuries. It can also protect organs, prevent stomach ulcers, and even heal skin burns.

BPC 157 Peptides or the Gastric Pentadecapeptide BPC 157 have also been found to have the promoting effect when it comes to tendon healing involving:

  • Tendon Outgrowth
  • Cell Survival
  • And Cell Mitigation

BPC 157 is also known to be a partial sequence from the human gastric protein BPC. It:

Has been found in isolated gastric juice

  • Found out to be stable and very much resistant to hydrolysis or enzyme digestion.
  • Easily dissolved in water.
  • Does not need any carrier to be applied.

Has been found to heal wounds such as:

  • Gastric ulcer
  • Skin
  • Cornea
  • Muscle
  • Colon-Colon Anastomosis
  • Colocutaneous Fistula
  • Segmental Bone Defect
  • Ulcers in the Stomach
  • Intestinal Damage (such as fistulas)
  • Inflammatory Disorders
  • Bone & Joint Healing Growth Rates
  • Organ Damage
  • Treatment for Celiac & Crohn’s disease

BPC-157 also helps in accelerating healing of wounds, increasing fibroblasts, improving Nitric Oxide, digestive function, and even enhancing vascular expression of VEGFR2.

When it comes to the healing of wounds, BPC 157 can heal such beyond just the surface as this can treat skin burns. It can even improve blood flow and increase collagen production. It also repairs ligaments and tendon-to-bone damage.

BPC-157 has also brought relief to people who suffer from muscle sprain, tears, and other types of injuries.

It helps your pancreas produce more insulin. Insulin helps control the body’s blood sugar. With blood sugar levels in a stable range, the body has to rely on storages of fuel (fat) for energy.

It slows down the emptying of your stomach after finishing a meal. You will feel fuller for longer, and it will take less food to give you the feeling of being full, thus reducing your caloric intake.

It reduces the glucagon hormone. Glucagon naturally increases the body’s blood sugar. Reducing this will encourage the body to use alternative forms of fuel, like fat, for energy.

It reduces the brain’s craving for food. The less you crave snacks and treats, the fewer empty calories you’ll be consuming.

  • Diabetic Retinopathy
  • Low Blood Sugar
  • Gallbladder Disease
  • Pancreatitis
  • Decreased Kidney Function
  • Medullary Thyroid Cancer
  • Multiple Endocrine Neoplasia Type 2
  • A Family History of Medullary Thyroid Carcinoma
  • Kidney Disease
  • Type 1 Diabetes
  • Diabetic Ketoacidosis